Elan Pharmaceuticals, Inc.

Plexxikon Inc.

Exelixis, Inc.

Symphony Evolution, Inc.

Shumeye Mamo

Prabha N Ibrahim

Varghese John

Jay S Tung

Lawrence Y Fang

Chao Zhang

Dean R Artis

Roy K Hom

Ryan Bremer

Andrea Gailunas

Jiazhong Zhang

Hanna Cho

Moon Jung Kim

Wei Xu

Wayne Spevak

John M Nuss

Marika Nespi

Vasu Jammalamadaka

Erick Wang Co

Shenghua Shi

Donna Tra Le

Rebecca Zuckerman

Samuel J Gillette

Brian L West

Morrison B Mac

Gideon Bollag

Klaus-Peter Hirth

Gaston G Habets

Yong-Liang Zhu

Lynne Canne Bannen

Michael P Prisbylla

S David Brown

Amy Lew Tsuhako

Heike I Krupka

Clarence R Hurt

Hongyao Zhu

Zhaoyang Wen

Ashley C Guinn

Abhinav Kumar

Jianming Tsai

Guoxian Wu

James Tsai

Yoshihisa Suzuki

Amy Lew

Rickard George Khoury

Lynne Canne-Bannen

Richard George Khoury

Byunghun Lee

Sam Gillette

Yong Zhu

Yoshisa Suzuki

Erick W Co

Helke Krupka

Richard Dean Artis

Gaston Habets

Heike Krupka

Dean Richard Artis

Moon Hwan Kim

Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

Compounds and methods for kinase modulation, and indications therefor

Compounds active on Ret are described, as well as methods of using such compounds. Also described are crystal structures of Ret surrogates that were determined using X-ray crystallography. The use of such Ret surrogate crystals and structural information can, for example, be used for identifying molecular scaffolds and for developing ligands that bind to and modulate Ret and for identifying improved ligands based on known ligands.

Compounds and methods for development of Ret modulators

The present invention provides compounds useful for inhibiting the ADAM-10 protein, with selectivity versus MMP-1. Such compounds are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role.

Human ADAM-10 inhibitors

The present invention provides compounds useful for inhibiting the ADAM-10 protein. Such compounds are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role. The invention also provides methods for making bis-aryl ether sulfonyl chlorides and ADAM-10 modulators therefrom.

Human adam-10 inhibitors

Compounds are described that are active on PDE4. Also described are crystal structures of PDE4B determined using X-ray crystallography, the use of PDE4B crystals and structural information for identifying molecular scaffolds, for developing ligands that bind to and modulate PDE4B, and for identifying improved ligands based on known ligands.

PDE4B inhibitors

Dipeptide derived inhibitors of the &#x3b2;-secretase enzyme are provided which are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A&#x3b2; peptide in a mammal. The compounds of the invention provide useful methods of treatment by administration of these inhibitors to reduce A&#x3b2; peptide formation and in pharmaceutical compositions.

Dipeptide inhibitors of &#x3b2;-secretase

Statine-derived peptide inhibitors of the &#x3b2;-secretase enzyme are provided which are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A&#x3b2; peptide in a mammal. The compounds of the invention provide useful methods of treatment by administration of these inhibitors to reduce A&#x3b2; peptide formation and pharmaceutical compositions.

Tetrapeptide inhibitors of &#x3b2;-secretase

The present invention is directed toward substituted hydroxyethylene compounds of formula (XII) useful in treating Alzheimer's disease and other similar diseases.

Methods to treat alzheimer's disease

The present invention is directed toward substituted hydroxyethylene compounds of formula (XII)useful in treating Alzheimer's disease and other similar diseases.

Compounds to treat Alzheimer's disease

Growing community of inventors

Oakland, CA, United States of America

Shumeye Mamo